Piper Sandler analyst Yasmeen Rahimi last night upgraded Korro Bio (KRRO) to Overweight from Neutral with a price target of $30, up from $11, following the analyst day. Piper left with “strong conviction” for KRRO-121’s probability of success. KRRO-121 is designed to reduce hyperammonemia through generation of stable, de-novo glutamine synthase variants, an approach supported by human genetic evidence, the analyst tells investors in a research note. Piper is bullish ahead of KRRO-121’s nwe drug filing in the second half of 2026, saying there is a “clear precedence for a regulatory path.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio upgraded to Overweight from Neutral at Piper Sandler
- Midday Fly By: AT&T reports Q4 beat, Amazon cuts 16,000 jobs
- Oppenheimer upgrades Korro Bio to Outperform as KRRO-121 offers fresh story
- Korro Bio upgraded to Outperform from Perform at Oppenheimer
- Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald